Contract manufacturing organization

EQS-News: Partners Group to acquire Pharmathen, a leading European pharmaceutical company, from BC Partners

Retrieved on: 
Monday, July 19, 2021
Finance, Money, BC Partners, Private equity, Contract manufacturing organization, Patheon

Partners Group to acquire Pharmathen, a leading European pharmaceutical company, from BC Partners

Key Points: 
  • Partners Group to acquire Pharmathen, a leading European pharmaceutical company, from BC Partners
    Partners Group, a leading global private markets firm, has, on behalf of its clients, agreed to acquire Pharmathen (or "the Company"), a leading European pharmaceutical company, from international investment firm BC Partners.
  • Founded in 1969, Pharmathen is a leading contract development and manufacturing organization ("CDMO") specialized in advanced drug delivery technologies for complex generic pharmaceutical products.
  • In particular, Partners Group will support the Company to accelerate its expansion in the US, by building out its on-the-ground presence.
  • Pascal Noth, Managing Director, Private Equity Europe, Partners Group, says: "Pharmathen is very well-regarded by the broader pharmaceutical industry as an innovative and forward-thinking company.

Evergreen Theragnostics Expands Alpha Radiopharmaceutical Production Capabilities

Retrieved on: 
Thursday, July 15, 2021
Contract manufacturing organization, Pharmaceutical industry, Evergreen, Software

SPRINGFIELD, N.J., July 15, 2021 /PRNewswire/ -- Evergreen Theragnostics, Inc., a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has undertaken an important strategic expansion at its manufacturing facility in Springfield, NJ

Key Points: 
  • SPRINGFIELD, N.J., July 15, 2021 /PRNewswire/ -- Evergreen Theragnostics, Inc., a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has undertaken an important strategic expansion at its manufacturing facility in Springfield, NJ
    With the Evergreen Springfield Facility set to open within the next two months, Evergreen has already begun expansion to build a GMP state-of-the-art alpha emitter production center, which will be integrated into Evergreen's existing facility.
  • The addition, opening in Q1 2022, will bolster Evergreen's ability to support alpha based radiopharmaceutical programs from pre-clinical pharmaceutical development to commercial manufacture and supply.
  • We firmly believe that this approach will greatly accelerate the delivery of novel treatments to patients," said James Cook, Evergreen Theragnostics CEO.
  • Evergreen Theragnostics, established in 2019, is a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO).

United States Pharmaceutical Drug Delivery Market Prospects, Trends Analysis, Market Size and Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Pharmaceutical, Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry, Pharmacology, Pharmacy, Drug pricing, Pharmaceutical industry in China, Contract manufacturing organization

The "United States Pharmaceutical Drug Delivery Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Pharmaceutical Drug Delivery Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The country research report on the United States pharmaceutical drug delivery market is a customer intelligence and competitive study of the United States market.
  • The companies and dealers/distributors profiled in the report include manufacturers & suppliers of pharmaceutical drug delivery market in the United States.
  • 5) What are the modes of entering the United States pharmaceutical drug delivery market?

Recro Enters Development and Manufacturing Agreement With New Client

Retrieved on: 
Tuesday, July 13, 2021
Contract manufacturing organization, Pharmaceutical industry, Life sciences, Cambrex Corporation

GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Recro; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a development and cGMP manufacturing agreement with a new client.

Key Points: 
  • GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Recro; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a development and cGMP manufacturing agreement with a new client.
  • Under the terms of the agreement, Recro will provide early-stage development and manufacturing services to support the clients ongoing clinical development of an orally administered, minimally-absorbed investigational compound.
  • This agreement continues the momentum that we have generated by leveraging our decades-long experience in robust commercial GMP manufacturing for clinical-stage programs.
  • Recro (NASD: REPH ) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing.

Global and China CDMO (Contract Development and Manufacturing Organization) Market Insight Report, 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Other Manufacturing, Manufacturing, Countries, Contract manufacturing organization, Pharmaceutical industry, Forms of government, China, World

The "Global and China CDMO (Contract Development and Manufacturing Organization) Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global and China CDMO (Contract Development and Manufacturing Organization) Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • We estimate that by 2025, the total size of the global CDMO market will be US$ 119.58 billion, with a compound growth rate of 11.2%.
  • In 2019, the total size of China's CDMO market was 44.1 billion yuan, of which the chemical CDMO scale was 39.22 billion yuan and the bio CDMO scale was 4.88 billion yuan.
  • Overall, China's CDMO industry will still maintain rapid growth, among which bio CDMO will grow faster.

LGM Pharma Launches Standalone Analytical Services for Drug Developers and Manufacturers

Retrieved on: 
Thursday, July 8, 2021
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Pharmaceutical industry, Contract manufacturing organization, Pharmacy, Compounding, Pharma, Applied sciences, Articles, Branches of science

LGM Pharma today announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies.

Key Points: 
  • LGM Pharma today announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies.
  • The company, which already conducts analytical services as part of its integrated contract development and manufacturing (CDMO) activities, now is offering its analytical services expertise and facilities as a standalone contract service for pharmaceutical industry clients.
  • We are delighted to be able to offer our first-rate analytical and stability testing services to the broader community of drug manufacturers and developers, said Shailesh Vengurlekar, Senior Vice President, Quality & Regulatory Affairs at LGM Pharma.
  • As a result, we now are able to provide a full suite of these services as a standalone option.

Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors

Retrieved on: 
Thursday, July 1, 2021
Contract manufacturing organization, Pharmaceutical industry

I am happy to express the boards excitement in welcoming Dr. Alegria as a new director, said Joseph Carleone, Ph.D., Avids chairman of the board.

Key Points: 
  • I am happy to express the boards excitement in welcoming Dr. Alegria as a new director, said Joseph Carleone, Ph.D., Avids chairman of the board.
  • We are all looking forward to working alongside Dr. Alegria and tapping into her vast biopharma industry expertise.
  • Dr. Alegria said, I am thrilled to have the opportunity to join the Avid board, which I believe is one of the most accomplished collection of directors within the CDMO industry.
  • The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization.

Pall Corporation Secures Multi-Million Dollar Contract With Exothera

Retrieved on: 
Thursday, July 1, 2021
Natural sciences, Pall Corporation, Pharmaceutical industry, Physical sciences, Chemistry, Filtration, Pall, Contract manufacturing organization, Downstream

PORT WASHINGTON, N.Y., July 1, 2021 /PRNewswire/ --Pall Corporation, a global leader in filtration, separation and purification, today announced a new contract worth more than $7M with full-service contract development and manufacturing organization (CDMO) Exothera S.A.

Key Points: 
  • PORT WASHINGTON, N.Y., July 1, 2021 /PRNewswire/ --Pall Corporation, a global leader in filtration, separation and purification, today announced a new contract worth more than $7M with full-service contract development and manufacturing organization (CDMO) Exothera S.A.
  • Exothera recently announced a significant expansion of its manufacturing capabilities, with two new state-of-the-art Good Manufacturing Practice (GMP) facilities built at the company's Jumet site near Brussels, Belgium.
  • Pall has considerable process development expertise from working with many of the industry leaders to develop scalable upstream and downstream processes.
  • Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry.

Woodstock Sterile Solutions Hires New Chief Financial Officer

Retrieved on: 
Monday, June 28, 2021
Pharmaceutical industry, Catskills, Counterculture of the 1960s, In music, Woodstock, Contract manufacturing organization, Geography of New York state), BFS, Counterculture, Geography of the United States

WOODSTOCK, Ill., June 28, 2021 /PRNewswire/ -- Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development and manufacturing organization (CDMO), has named Courtney Sanen as its first Chief Financial Officer (CFO).

Key Points: 
  • WOODSTOCK, Ill., June 28, 2021 /PRNewswire/ -- Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development and manufacturing organization (CDMO), has named Courtney Sanen as its first Chief Financial Officer (CFO).
  • "Woodstock Sterile Solutions is poised for growth over the coming years, and experience among our leadership team is critical to our future success," says Woodstock Sterile Solutions CEO Paul Josephs.
  • "It is exciting to join Woodstock Sterile Solutions during this pivotal time, as they start out as an independent organization.
  • For 50 years, Woodstock Sterile Solutions has been recognized as a leading Blow-Fill-Seal (BFS) Contract Development and Manufacturing Organization (CDMO).

Samsung Biologics Issues Its First Annual Sustainability Report

Retrieved on: 
Friday, June 25, 2021
Life sciences, Companies, Industry economics), Pharmaceutical industry, Samsung, Samsung Biologics, Biotechnology, Contract manufacturing organization, Biopharmaceutical

INCHEON, South Korea, June24, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company's policies for an enhanced ESG management system and related plans.

Key Points: 
  • INCHEON, South Korea, June24, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company's policies for an enhanced ESG management system and related plans.
  • John Rim, CEO of Samsung Biologics, said, "The publication of our annual sustainability report showcases our aims to accelerate innovation and contribute to building a healthier future for all stakeholders.
  • In the report, Samsung Biologics stated its plans to build an eco-friendly business environment, supported by recently awarded ISO Certifications for Energy Management (ISO5000) and Occupational Health and Safety Management (ISO45001).
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.